Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 15/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303920 | 0.85 | LMNA (0.63) | OPRM1OPRK1OPRL1LMNAOPRD1 | |
| SCHEMBL2707046 | 0.85 | LMNA (0.63) | OPRM1OPRK1OPRL1LMNAOPRD1 | |
| SCHEMBL890213 | 0.84 | OPRM1 (0.53) | OPRM1OPRK1OPRL1LMNAOPRD1 | |
| SCHEMBL14479493 | 0.84 | OPRM1 (0.53) | OPRM1OPRK1OPRL1LMNAOPRD1 | |
| SCHEMBL8915944 | 0.83 | LMNA (0.65) | LMNAOPRD1GAAALDH1A1MEN1 | |
| SCHEMBL13187482 | 0.83 | LMNA (0.65) | LMNAOPRD1GAAALDH1A1MEN1 | |
| SCHEMBL13748125 | 0.82 | OPRM1 (0.52) | OPRM1OPRK1OPRL1LMNAOPRD1 | |
| SCHEMBL10151018 | 0.82 | GAA (0.66) | LMNAOPRD1GAAALDH1A1MEN1 | |
| SCHEMBL14478021 | 0.81 | OPRM1 (0.51) | OPRM1OPRK1OPRL1LMNAOPRD1 | |
| SCHEMBL888780 | 0.81 | OPRM1 (0.51) | OPRM1OPRK1OPRL1LMNAOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | OPRM1 2184/4885OPRK1 1982/4885OPRL1 3713/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | OPRM1 2228/4885OPRK1 1860/4885OPRL1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.